DE602006012801D1 - Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetika - Google Patents
Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetikaInfo
- Publication number
- DE602006012801D1 DE602006012801D1 DE602006012801T DE602006012801T DE602006012801D1 DE 602006012801 D1 DE602006012801 D1 DE 602006012801D1 DE 602006012801 T DE602006012801 T DE 602006012801T DE 602006012801 T DE602006012801 T DE 602006012801T DE 602006012801 D1 DE602006012801 D1 DE 602006012801D1
- Authority
- DE
- Germany
- Prior art keywords
- benzyl
- hydroxy
- analgetics
- propylamines
- diamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64727105P | 2005-01-26 | 2005-01-26 | |
PCT/US2006/002505 WO2006081252A2 (en) | 2005-01-26 | 2006-01-25 | Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602006012801D1 true DE602006012801D1 (de) | 2010-04-22 |
Family
ID=36250723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602006012801T Active DE602006012801D1 (de) | 2005-01-26 | 2006-01-25 | Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetika |
Country Status (20)
Country | Link |
---|---|
US (11) | US8153666B2 (de) |
EP (7) | EP1841743B1 (de) |
JP (6) | JP5042040B2 (de) |
KR (1) | KR101395382B1 (de) |
CN (2) | CN101151248B (de) |
AT (3) | ATE523491T1 (de) |
AU (4) | AU2006209209B2 (de) |
BR (5) | BRPI0607304A2 (de) |
CA (4) | CA2595544C (de) |
DE (1) | DE602006012801D1 (de) |
DK (3) | DK1841743T3 (de) |
ES (5) | ES2340196T3 (de) |
HK (2) | HK1145628A1 (de) |
HU (1) | HUE028654T2 (de) |
MX (1) | MX2007008955A (de) |
NZ (1) | NZ556614A (de) |
PL (2) | PL1841743T3 (de) |
RU (1) | RU2433999C2 (de) |
WO (4) | WO2006081276A1 (de) |
ZA (1) | ZA200706010B (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0517701A8 (pt) | 2004-11-10 | 2018-01-23 | Genzyme Corp | métodos de tratamento de diabetes mellitus |
ATE523491T1 (de) * | 2005-01-26 | 2011-09-15 | Allergan Inc | 3-heterocyclyl-3-hydroxy-2-amino-propionsäure- amide und damit zusammenhängende verbindungen mit analgesischer und/oder immunostimulatorischer aktivität |
PL2032134T3 (pl) | 2006-05-09 | 2015-11-30 | Genzyme Corp | Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów |
WO2008011485A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain |
WO2008011483A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
WO2008011487A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain |
WO2008011478A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
WO2008109285A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders |
US20140179925A1 (en) | 2009-09-04 | 2014-06-26 | Allergan, Inc. | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
US9314466B2 (en) | 2007-03-06 | 2016-04-19 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
BRPI0808353B8 (pt) | 2007-03-06 | 2021-05-25 | Allergan Inc | usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados |
CN101279955B (zh) * | 2007-04-03 | 2012-11-28 | 北京摩力克科技有限公司 | 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途 |
EP2594565B1 (de) | 2007-05-31 | 2018-10-24 | Genzyme Corporation | Glukosylceramid-Synthase-Hemmer vom 2-Acylaminpropanol-Typ |
WO2009012082A1 (en) * | 2007-07-17 | 2009-01-22 | Allergan, Inc. | Methods for treating anxiety |
WO2009045503A1 (en) | 2007-10-05 | 2009-04-09 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
US8168631B2 (en) | 2008-02-05 | 2012-05-01 | Allergan, Inc. | 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity |
WO2010014554A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
EP2349255B1 (de) | 2008-10-03 | 2016-03-30 | Genzyme Corporation | Glucosylceramidsynthaseinhibitoren vom 2-acylaminopropoanoltyp |
BR112012001047A2 (pt) | 2009-07-17 | 2019-09-24 | Allergan Inc | composições compreendendo um inibidor de colinesterase para tratar distúrbios cognitivos |
US8242141B2 (en) * | 2009-09-16 | 2012-08-14 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
JP2013505246A (ja) * | 2009-09-16 | 2013-02-14 | アラーガン インコーポレイテッド | 痙縮を治療するための化合物及び方法 |
CA2774357A1 (en) | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating disorders of gastrointestinal motility |
PL2501693T3 (pl) | 2009-11-18 | 2015-03-31 | Fab Pharma Sas | Azaheterocykliczne akryloamidy i ich zastosowanie jako środków bakteriobójczych |
EP3336079A1 (de) | 2013-08-15 | 2018-06-20 | Allergan, Inc. | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(l)-(+)-tartratsalz, dessen verfahren zur herstellung und verwendung |
TW201945337A (zh) | 2013-09-20 | 2019-12-01 | 美商拜奧馬林製藥公司 | 用於治療疾病之葡萄糖苷基腦醯胺(glucosylceramide)合成酶抑制劑 |
JP6152816B2 (ja) * | 2014-03-26 | 2017-06-28 | ソニー株式会社 | 半導体デバイス、表示パネル、表示装置、電子装置、および、半導体デバイスの製造方法 |
DE102015217629A1 (de) * | 2015-09-15 | 2017-03-16 | Tridonic Gmbh & Co Kg | PFC-Modul für lückenden Betrieb |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2514380A (en) * | 1946-12-26 | 1950-07-11 | Hoffmann La Roche | Diamines and method of production |
DE1001261C2 (de) | 1954-08-05 | 1957-07-04 | Thomae Gmbh Dr K | Verfahren zur Herstellung von basischen Estern endocyclisch substituierter Mandelsaeuren und ihren Salzen |
US2918466A (en) | 1955-05-24 | 1959-12-22 | Univ St Johns | Antimicrobial chemical compounds derived from alkoxyphenyl glycidic acid |
US3065265A (en) | 1957-07-04 | 1962-11-20 | Hoffmann La Roche | Amino acid hydrazides |
SU1063026A1 (ru) | 1982-05-19 | 1990-12-07 | Институт биохимии АН ЛитССР | N @ -Бензолсульфонильные производные трес-DL-фенилсерина, обладающие противовоспалительной активностью |
EP0144290A3 (de) * | 1983-12-01 | 1987-05-27 | Ciba-Geigy Ag | Substituierte Aethylendiaminderivate |
JPS60132935A (ja) | 1983-12-20 | 1985-07-16 | Sumitomo Chem Co Ltd | フエニルセリン誘導体及びその製造方法 |
JPS61145148A (ja) | 1984-12-19 | 1986-07-02 | Sumitomo Seiyaku Kk | フエニルセリン誘導体 |
GB8618188D0 (en) * | 1986-07-25 | 1986-09-03 | Ici Plc | Diamine compounds |
GB8622352D0 (en) * | 1986-09-17 | 1986-10-22 | Zambeleetti Spa Dr L | Compounds |
JPH02250845A (ja) | 1989-03-22 | 1990-10-08 | Sumitomo Pharmaceut Co Ltd | 3―(4―フルオロフェニル)プロピオンアルデヒドの製造方法 |
ATE152102T1 (de) * | 1991-05-10 | 1997-05-15 | Takeda Chemical Industries Ltd | Pyridinderivate, deren herstellung und anwendung |
JPH0550499A (ja) | 1991-08-27 | 1993-03-02 | Kuwabara Yasunaga | 成形型内におけるトリミング方法及び容器 |
US6696486B1 (en) | 1992-01-22 | 2004-02-24 | Glaxo Group Limited | Medical use for atypical β-adrenoceptor agonists |
CN1128951A (zh) | 1993-08-13 | 1996-08-14 | 生化学工业株式会社 | 治疗神经元疾病的药物 |
JPH09506610A (ja) | 1993-12-17 | 1997-06-30 | ディーエスエム エヌ.ブイ. | フェニルセリンアミド、及びフェニルセリン/フェニルセリンアミド の調製 |
DE69524592T2 (de) | 1994-06-10 | 2002-07-18 | Seikagaku Kogyo Co Ltd | 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung |
EP0782631A4 (de) * | 1994-09-19 | 1999-03-24 | Univ Leland Stanford Junior | Behandlung gegen plasmodium |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
FR2732894B1 (fr) | 1995-04-13 | 1997-07-04 | Sanofi Sa | Nouvelle utilisation de composes agonistes beta9-adrenergiques |
JPH08337569A (ja) * | 1995-06-15 | 1996-12-24 | Sankyo Co Ltd | 鎮痛活性物質 |
WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US5916911A (en) * | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
NO965193L (no) * | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
JP3993908B2 (ja) * | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
DE19601745C1 (de) | 1996-01-19 | 1997-10-09 | Gruenenthal Gmbh | Verfahren zur Racematspaltung von Tramadol |
EP0848059A1 (de) | 1996-12-12 | 1998-06-17 | Vetigen | ICYP (Iodocyanopindolol) Rezeptor von Säugetieren und dessen Anwendungen |
AU5923998A (en) * | 1997-01-31 | 1998-08-25 | Avid Therapeutics Inc. | 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same |
US6573387B1 (en) * | 1997-03-21 | 2003-06-03 | The Scripps Research Institute | Synthesis of α,β-substituted amino amides, esters, and acids |
JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
SE9904197D0 (sv) | 1999-11-22 | 1999-11-22 | Amersham Pharm Biotech Ab | A method for anion exchange adsorption on matrices carrying mixed mode ligands |
US6407064B2 (en) | 1999-12-06 | 2002-06-18 | Seikagaku Corporation | Aminoalcohol derivative and medicament comprising the same |
WO2001047874A1 (en) * | 1999-12-24 | 2001-07-05 | Smithkline Beecham P.L.C. | (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
KR20000063913A (ko) | 2000-08-10 | 2000-11-06 | 하현준 | 아지리딘으로부터 1,2-디아미노프로판 알코올을 제조하는방법 |
US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
EP1358172B1 (de) | 2001-01-10 | 2009-11-18 | The Regents of The University of Michigan | Aminoceramidartige verbindungen und therapeutische anwendungen |
BRPI0211379B8 (pt) * | 2001-07-16 | 2021-05-25 | Genzyme Corp | síntese de inibidores de udp-glicose: n-acil-esfingosina glicosiltransferase |
WO2003013571A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
WO2003045928A1 (en) * | 2001-11-26 | 2003-06-05 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
JP2006021997A (ja) | 2002-07-09 | 2006-01-26 | Ono Pharmaceut Co Ltd | cysLT1/cysLT2両受容体拮抗性呼吸器疾患治療剤 |
WO2004050022A2 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
ES2552247T3 (es) | 2003-01-08 | 2015-11-26 | The University Of Washington | Agentes antibacterianos |
CN1890228B (zh) | 2003-12-11 | 2011-07-20 | 田边三菱制药株式会社 | α-氨基酸衍生物及其作为药物的应用 |
WO2005063275A1 (en) | 2003-12-23 | 2005-07-14 | Musc Foundaton For Research Development | Methods and compositions for the prevention and treatment of inflammatory diseases or conditions |
US20070093492A1 (en) | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
EP1781331A1 (de) | 2004-08-09 | 2007-05-09 | Université Catholique de Louvain | Verwendung von agonisten und antagonisten von beta-adrenozeptoren zur behandlung von arterienerkrankungen |
DE102004053409A1 (de) | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Verfahren zur gezielten Herstellung von Lysobactinfragmenten |
ATE523491T1 (de) * | 2005-01-26 | 2011-09-15 | Allergan Inc | 3-heterocyclyl-3-hydroxy-2-amino-propionsäure- amide und damit zusammenhängende verbindungen mit analgesischer und/oder immunostimulatorischer aktivität |
US7858825B2 (en) | 2007-02-15 | 2010-12-28 | Colorado State University Research Foundation | Acid and base stable diphenylmethanol derivatives and methods of use |
WO2008109285A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders |
BRPI0808353B8 (pt) * | 2007-03-06 | 2021-05-25 | Allergan Inc | usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados |
WO2008109286A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
WO2009012082A1 (en) * | 2007-07-17 | 2009-01-22 | Allergan, Inc. | Methods for treating anxiety |
US8168631B2 (en) | 2008-02-05 | 2012-05-01 | Allergan, Inc. | 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity |
US8124648B2 (en) * | 2008-05-20 | 2012-02-28 | Allergan, Inc. | Therapeutic lactams |
JP2013505246A (ja) * | 2009-09-16 | 2013-02-14 | アラーガン インコーポレイテッド | 痙縮を治療するための化合物及び方法 |
CA2774357A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating disorders of gastrointestinal motility |
US8242141B2 (en) * | 2009-09-16 | 2012-08-14 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
-
2006
- 2006-01-25 AT AT06719438T patent/ATE523491T1/de not_active IP Right Cessation
- 2006-01-25 WO PCT/US2006/002570 patent/WO2006081276A1/en active Application Filing
- 2006-01-25 US US11/814,593 patent/US8153666B2/en active Active
- 2006-01-25 BR BRPI0607304-2A patent/BRPI0607304A2/pt not_active Application Discontinuation
- 2006-01-25 ES ES06719390T patent/ES2340196T3/es active Active
- 2006-01-25 ES ES06719438T patent/ES2371265T3/es active Active
- 2006-01-25 WO PCT/US2006/002505 patent/WO2006081252A2/en active Application Filing
- 2006-01-25 CA CA2595544A patent/CA2595544C/en not_active Expired - Fee Related
- 2006-01-25 HU HUE06719422A patent/HUE028654T2/en unknown
- 2006-01-25 WO PCT/US2006/002557 patent/WO2006081273A1/en active Application Filing
- 2006-01-25 PL PL06719422T patent/PL1841743T3/pl unknown
- 2006-01-25 ES ES10155753T patent/ES2380904T3/es active Active
- 2006-01-25 CN CN2006800098658A patent/CN101151248B/zh active Active
- 2006-01-25 MX MX2007008955A patent/MX2007008955A/es active IP Right Grant
- 2006-01-25 AU AU2006209209A patent/AU2006209209B2/en active Active
- 2006-01-25 DK DK06719422.5T patent/DK1841743T3/en active
- 2006-01-25 DE DE602006012801T patent/DE602006012801D1/de active Active
- 2006-01-25 WO PCT/US2006/002580 patent/WO2006081280A1/en active Application Filing
- 2006-01-25 BR BRPI0606112A patent/BRPI0606112B8/pt active IP Right Grant
- 2006-01-25 AT AT10155753T patent/ATE549020T1/de active
- 2006-01-25 DK DK06719438.1T patent/DK1841756T3/da active
- 2006-01-25 EP EP06719422.5A patent/EP1841743B1/de active Active
- 2006-01-25 EP EP12159632.4A patent/EP2474534B1/de active Active
- 2006-01-25 KR KR1020077019382A patent/KR101395382B1/ko active IP Right Grant
- 2006-01-25 PL PL383715A patent/PL383715A1/pl unknown
- 2006-01-25 NZ NZ556614A patent/NZ556614A/en unknown
- 2006-01-25 CA CA2595522A patent/CA2595522C/en active Active
- 2006-01-25 ES ES06719433.2T patent/ES2436612T3/es active Active
- 2006-01-25 BR BR122018068138A patent/BR122018068138B8/pt active IP Right Grant
- 2006-01-25 EP EP06719433.2A patent/EP1841742B1/de active Active
- 2006-01-25 EP EP06719438A patent/EP1841756B1/de active Active
- 2006-01-25 EP EP10155753A patent/EP2198864B1/de active Active
- 2006-01-25 US US11/814,598 patent/US8288556B2/en active Active
- 2006-01-25 AU AU2006209197A patent/AU2006209197A1/en not_active Abandoned
- 2006-01-25 BR BRPI0606111A patent/BRPI0606111B8/pt active IP Right Grant
- 2006-01-25 US US11/814,601 patent/US8013000B2/en active Active
- 2006-01-25 CA CA2595519A patent/CA2595519C/en not_active Expired - Fee Related
- 2006-01-25 CN CN201210113463.XA patent/CN102718748B/zh active Active
- 2006-01-25 DK DK06719390.4T patent/DK1841423T3/da active
- 2006-01-25 AU AU2006209207A patent/AU2006209207C1/en not_active Ceased
- 2006-01-25 ES ES06719422.5T patent/ES2565236T3/es active Active
- 2006-01-25 RU RU2007128313/04A patent/RU2433999C2/ru active
- 2006-01-25 US US11/814,604 patent/US20090088433A1/en not_active Abandoned
- 2006-01-25 AU AU2006209208A patent/AU2006209208B2/en not_active Ceased
- 2006-01-25 AT AT06719390T patent/ATE460159T1/de not_active IP Right Cessation
- 2006-01-25 JP JP2007553191A patent/JP5042040B2/ja not_active Expired - Fee Related
- 2006-01-25 JP JP2007553179A patent/JP5039564B2/ja not_active Expired - Fee Related
- 2006-01-25 CA CA002595542A patent/CA2595542A1/en not_active Abandoned
- 2006-01-25 EP EP06719390A patent/EP1841423B1/de active Active
- 2006-01-25 BR BRPI0607379A patent/BRPI0607379B8/pt active IP Right Grant
- 2006-01-25 JP JP2007553193A patent/JP5107058B2/ja active Active
- 2006-01-25 EP EP12161266.7A patent/EP2489658B1/de active Active
- 2006-01-25 JP JP2007553188A patent/JP5042039B2/ja active Active
-
2007
- 2007-07-20 ZA ZA200706010A patent/ZA200706010B/xx unknown
-
2010
- 2010-12-22 HK HK10111996.9A patent/HK1145628A1/xx not_active IP Right Cessation
-
2011
- 2011-08-02 US US13/196,132 patent/US8513288B2/en active Active
-
2012
- 2012-03-01 US US13/409,853 patent/US8835463B2/en active Active
- 2012-04-04 JP JP2012085676A patent/JP2012162546A/ja active Pending
- 2012-04-04 JP JP2012085680A patent/JP2012162547A/ja active Pending
- 2012-04-19 US US13/450,854 patent/US9278943B2/en active Active
- 2012-09-12 US US13/612,260 patent/US8431599B2/en active Active
-
2013
- 2013-01-09 HK HK13100295.7A patent/HK1173721A1/xx unknown
- 2013-03-15 US US13/834,336 patent/US8927589B2/en active Active
- 2013-07-24 US US13/949,468 patent/US9399628B2/en active Active
-
2015
- 2015-11-30 US US14/954,263 patent/US9828349B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602006012801D1 (de) | Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetika | |
CY1111241T1 (el) | Μεθοδος μειωσης α,β-ακορεστων κετονων σε οπιοεiδεις συνθεσεις | |
ATE430150T1 (de) | 8-ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer | |
DE602005010961D1 (de) | Phenylcarbazole basierte Verbindungen und deren Verwendung als organische Elektroluminiszierende Vorrichtung | |
DE602006015928D1 (de) | Acylierte glp-1 verbindungen | |
ATE528300T1 (de) | Bizyklische verbindungen und ihre verwendung als antidiabetika | |
NO20082598L (no) | ERBB-inhibitorer | |
ATE542803T1 (de) | Verfahren zur herstellung von dihydrochinazolinen | |
BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias | |
ATE462701T1 (de) | Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin 1-carboxylsäure- derivaten und damit zusammenhängenden verbindungen | |
TW200700358A (en) | Organic compounds | |
DE602005011113D1 (de) | Morphinanderivate als mittel gegen juckreiz | |
CY1112555T1 (el) | Διεργασια χημικης συζευξης με ενα παραγωγο φαινυλ βορονικου οξεος | |
CY1113916T1 (el) | Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης | |
CY1112919T1 (el) | Παραγωγα β-αμινοξεων για τη θεραπευτικη αντιμετωπιση του διαβητη | |
ATE498600T1 (de) | Inden derivate als pharmazeutika | |
CY1111432T1 (el) | Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5 | |
ATE357967T1 (de) | Emulsionen mit oberflächenmodifizierten organischen molekülen | |
DE112008003640A5 (de) | Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-Triazin-Derivaten | |
ATE371662T1 (de) | Siliziumverbindungen und deren verwendung | |
ATE445592T1 (de) | Derivate von heteroarylalkylcarbamaten, verfahren zu deren herstellung und deren verwendung als faah-enzyminhibitoren | |
ATE508130T1 (de) | 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren | |
WO2004013122A3 (de) | Oktupolare moleküle als organische halbleiter | |
ATE374778T1 (de) | Organosiliziumverbindungen und deren verwendung | |
BRPI0506996A (pt) | compostos orgánicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |